{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable due to low number of events.","groupId":"OG000","lowerLimit":"34.0","upperLimit":"NA","value":"37.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"description":"Duration of CR, defined for subjects who achieve CR according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014) as the time from the first occurrence of CR to disease progression or death, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were treated with ibrutinib 560 mg and venetoclax (starting at 20 mg, and gradually ramped up to a target dose of 400 mg).","id":"OG000","title":"Treatment-naive Open-label Arm"}],"paramType":"MEDIAN","populationDescription":"All Enrolled Treatment-Naïve Subjects Achieving CR","reportingStatus":"POSTED","timeFrame":"For an overall median time on study of 40.51 months","title":"Duration of CR (Treatment-Naive Arm)","type":"SECONDARY","unitOfMeasure":"months"}